News & Events about Axogen Inc.
StockNews.com upgraded shares of AxoGen (NASDAQ:AXGN Get Rating) from a hold rating to a buy rating in a report issued on Tuesday. Several other brokerages also recently weighed in on AXGN. JMP Securities reaffirmed a market outperform rating and set a $20.00 target price on shares of AxoGen...
JMP Securities reiterated their market outperform rating on shares of AxoGen (NASDAQ:AXGN Get Rating) in a research report sent to investors on Wednesday, Benzinga reports. JMP Securities currently has a $20.00 price objective on the medical equipment providers stock. Separately, StockNews.com ...
ALACHUA, Fla. and TAMPA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2022 revenue. Preliminary ...
Study concluded allograft and autograft repairs delivered significantly better rates of meaningful sensory recovery in short gaps as compared to conduit repairs in a systematic meta-analysis including over 1,500 nerve repairs across 35 studiesALACHUA, Fla. and TAMPA, Fla., Jan. 05, 2023 (GLOBE ...
ALACHUA, Fla. and TAMPA, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Bri Majsiak, a Resensation patient, has been selected to ride on the 2023 Donate...